Current Report Filing (8-k)
May 17 2019 - 04:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 17, 2019
Precision
Therapeutics Inc.
(Exact name of Registrant as Specified
in its Charter)
Delaware
|
001-36790
|
83-4360734
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2915 Commers Drive, Suite 900
Eagan, Minnesota
|
55121
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including
area code:
(651) 389-4800
Former Name or Former Address, if Changed
Since Last Report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.01 par value
|
AIPT
|
Nasdaq Capital Market
|
Item 7.01 Regulation FD Disclosure.
On May 17, 2019, Precision Therapeutics Inc. released a corporate
presentation. The presentation is furnished as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(a) Not
applicable.
(b) Not
applicable.
(c) Not
applicable.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
PRECISION THERAPEUTICS inc.
|
|
|
|
By:
|
/s/ Bob Myers
|
|
|
|
Name: Bob Myers
Title: Chief Financial Officer
|
Date: May 17, 2019
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Mar 2023 to Mar 2024